[1]于娜, 周家为, 李霞, 等. 成人特发性肺纤维化(更新)和进行性肺纤维化临床实践指南(2022版)解读[J]. 中国现代医学杂志, 2023,33:1-8. [2]Tian M, Zhu X, Ren L, et al. HE4-based nomogram for predicting overall survival in patients with idiopathic pulmonary fibrosis: construction and validation[J]. Eur J Med Res, 2024,29:238. [3]Man R K, Gogikar A, Nanda A, et al. A comparison of the effectiveness of nintedanib and pirfenidone in treating idiopathic pulmonary fibrosis: a systematic review[J]. Cureus, 2024,16:e54268.doi: 10.7759/cureus.54268. [4]Maracci C, Motta S, Romagnoli A, et al. The mTOR/4E-BP1/eIF4E signalling pathway as a source of cancer drug targets[J]. Curr Med Chem, 2022,29:3501-3529. [5]Ren C, Wang Q, Fan S, et al. Toll-like receptor 9 aggravates pulmonary fibrosis by promoting NLRP3-mediated pyroptosis of alveolar epithelial cells[J]. Inflammation, 2024,47:1744-1761. [6]Liu Y, Wang D, Liu X, et al. Biological and pharmacolo-gical roles of pyroptosis in pulmonary inflammation and fibrosis: recent advances and future directions[J]. Cell Commun Signal, 2024,22:586.doi: 10.1186/s12964-024-01966-3. [7]朱山飞, 张建松, 郝定盈, 等. 柴胡皂苷d通过抑制炎性反应减轻大鼠肝脏缺血再灌注损伤[J]. 中华实验外科杂志, 2024,41:2006-2010. [8]袁林, 李万利, 靳玮, 等. 柴胡皂苷的生物学功能研究进展[J]. 中国兽医学报, 2024,44:1307-1315. [9]Feng S, Li K, Lv W, et al. Extraction, characterization, antioxidation and anti-inflammatory activity of polysaccharides from Bupleurum chinense based on different molecular weights[J]. Nat Prod Res, 2025,39:5832-5842. [10]袁林, 李万利, 靳玮, 等. 柴胡皂苷的生物学功能研究进展[J]. 中国兽医学报, 2024,44:1307-1315. [11]李耀征, 白保强, 孙亚勤, 等. 基于Nox4/PKCα/Gal-3通路探讨柴胡皂苷D对心肌梗死大鼠心肌纤维化的影响[J]. 中西医结合心脑血管病杂志, 2023,21:3724-3729. [12]Rao Z, Zhu Y, Yang P, et al. Pyroptosis in inflammatory diseases and cancer[J]. Theranostics, 2022,12:4310-4329. [13]高芳, 李君, 郭艳霞, 等. 柴胡皂苷D通过NLRP3介导细胞焦亡抑制未分化甲状腺癌细胞增殖的机制研究[J]. 湖南中医药大学学报, 2024,44:1794-1800. [14]孙路, 马欣, 刘运峰, 等. 柴胡皂苷D调控糖酵解抑制乳腺癌细胞增殖的机制研究[J]. 解剖科学进展, 2024,30:405-408. [15]Jia R, Meng D, Geng W. Advances in the anti-tumor mechanisms of saikosaponin D[J]. Pharmacol Rep, 2024,76:780-792. |